<DOC>
	<DOCNO>NCT02374372</DOCNO>
	<brief_summary>The site clinical trial conduct St-Luc hospital CHUM . This prospective randomized study compare two treatment modality , HD HDF , economics pharmaco-economics parameter . Patients , previously randomize CONTRAST study , remain respective group monitoring continue . The next patient randomized way ( 1 : 1 ) use inclusion exclusion criterion . HDF randomize patient receive post-dilution standard reinjection ( least 100ml/min 6 liter/hr ) . In rare case , HDF patient briefly reinjection pre-dilution mode ( heparin need avoid example ) reinjection flow adjust accordingly ( 200ml/min ) . Length frequency session 2 group . Blood test change use routine assessment . Metabolic control patient maintain accord guideline . Patients monitor minimum 3 year . A set demographic clinical data collect patient medical record throughout study . Biochemical data part usual blood test dialysis patient collect month well store analyze information annual cardiac ultrasound . All event score ( hospitalization , pattern , duration ) list cost drug compile every three month . These data useful economic analysis compare two treatment modality .</brief_summary>
	<brief_title>Comparing Hemodiafiltration On-line Conventional Hemodialysis Terms Cost-benefit</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<mesh_term>Kidney Failure , Chronic</mesh_term>
	<criteria>18 year old , able consent , patient need hemodialysis 812 hour week ( 23 session ) severe none compliance ( often miss session without good reason ) , life expectation le 3 month , treat highflux filter last 6 month</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>hemodialysis</keyword>
	<keyword>beta microglobulin</keyword>
	<keyword>amyloidosis</keyword>
</DOC>